Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wound Care: Medtech's New Billion Dollar Product Market

Executive Summary

For some time now, investors have hated wound care. They've been scarred by past failures, most famously, the simultaneous bankruptcies in 2002 of Advanced Tissue Sciences and Organogenesis, two tissue-engineering companies targeting chronic wounds. "Show me one success," VCs tell start-ups seeking funding. Well, now there is one. Kinetic Concepts is pulling in a billion dollars in revenues from a single product in the advanced wound care market. Is it time for VCs to love advanced wound care? Five new device start-ups hope so. Three are developing therapeutic devices for chronic wounds and two are beginning in acute wound care, an emerging surgical market. (A Reprint of "Advanced Wound Care: The Device Industry's Billion Dollar Product Market," appearing in START-UP, November 2007.

You may also be interested in...



Wound Care Devices: Growth Amid Uncertainty

Over the last 15 years, a trend toward evidence-based medicine has led to a greater understanding of the science behind wound healing. This knowledge has fueled an explosion of innovation in technology and in the commercialization of a wide range of new products, generating a worldwide market estimated at $4.5 billion annually, with double-digit growth projected over the next three to five years.

Tenaxis Medical Inc.

With a novel biomaterial that can be formulated into specialized products across a broad range of surgical applications, Tenaxis Medical Inc. aims to deliver on the initial promise of sealants to reduce procedure times, increase patient throughput, and improve the quality of patient care across a broad range of surgeries.

MediWound Ltd.

The first step in treating serious burns is to remove the burned layer of skin, or eschar. MediWound is developing a minimally invasive enzymatic alternative to the current gold standard: surgical excision. Its Debrase Gel Dressing, derived from pineapple plants, is highly selective for necrotic tissue. When topically applied to the burn site, it quickly digests and removes the eschar, leaving a clean wound bed.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT035129

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel